Huangpu pharmaceutical company teams with JNU for R&D

Lixin Pharmaceuticals Co Ltd signs agreements with Jinan University on June 8. [Photo by Li Jianjun]

Lixin Pharmaceuticals Co Ltd has signed up agreements with Jinan University (JNU) on June 8 to carry out industry-university-research cooperation in JNU's first-class disciplines, as well as to transfer the outcomes of a new medicine project.

The two sides will work together on the establishment of a laboratory for the research and development of medicine. Lixin Pharmaceuticals Co Ltd will invest 10 million yuan ($1.42 million) in building a technological R&D platform for new tumor immunosuppressive medicine, while launching the transfer and development of JND32066.

JND32066 is a new antineoplastic multi-kinase inhibitor that is a result of the early-stage cooperation between the company and JNU, which boasts great potential for future development. 

The company will strive to get the exclusive development rights of JND32066 on the global market with 100 million yuan.

The cooperation is expected to make innovations in the deeper integration between industry and education, accelerate the transfer of major innovative scientific outcomes in medicine, as well as better serve the high-quality development of the biomedicine industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

Set up in Guangzhou's Huangpu district in 2013, Lixin Pharmaceuticals Co Ltd has developed into a high-tech biomedicine company spanning R&D, manufacturing, and marketing.

Share - WeChat